Glenmark Pharma Goa Facility Receives US FDA EIR with VAI Status

Glenmark Pharmaceuticals Ltd. has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India. The facility has been classified with a Voluntary Action Indicated (VAI) status. The inspection took place from June 22, 2026, to June 30, 2026. This classification suggests that while the FDA noted some observations, they do not currently warrant mandatory regulatory action, indicating a generally satisfactory inspection outcome for the facility.